Document Detail


New promising drug targets in cancer- and metastasis-initiating cells.
MedLine Citation:
PMID:  20338259     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutic treatments against highly aggressive, metastatic, recurrent, and lethal cancers.
Authors:
Murielle Mimeault; Surinder K Batra
Related Documents :
20347589 - Rhogdi signaling provides targets for cancer therapy.
361139 - The current role of cancer chemotherapy.
18221149 - Development of small-molecule inhibitors of raf.
15072769 - Targeting hypoxia tolerance in cancer.
18226859 - Targeted therapy for uveal melanoma.
20836759 - Versatile applications of microrna in anti-cancer drug discovery: from therapeutics to ...
11682569 - Age-associated increase of 8-hydroxydeoxyguanosine in human colorectal tissue dna.
15254719 - The localisation and reduction of nuclear staining of ppargamma and pgc-1 in human brea...
16682259 - Screening for early pancreatic neoplasia in high-risk individuals: a prospective contro...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2010-03-23
Journal Detail:
Title:  Drug discovery today     Volume:  15     ISSN:  1878-5832     ISO Abbreviation:  Drug Discov. Today     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-05     Completed Date:  2010-07-22     Revised Date:  2010-12-03    
Medline Journal Info:
Nlm Unique ID:  9604391     Medline TA:  Drug Discov Today     Country:  England    
Other Details:
Languages:  eng     Pagination:  354-64     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA. mmimeault@unmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / administration & dosage*,  pharmacology*
Drug Delivery Systems / methods*
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor / methods
Drugs, Investigational / administration & dosage*,  pharmacology*
Humans
Models, Biological
Neoplasm Metastasis / prevention & control*
Signal Transduction / drug effects
Grant Support
ID/Acronym/Agency:
CA111294/CA/NCI NIH HHS; CA131944/CA/NCI NIH HHS; CA133774/CA/NCI NIH HHS; CA78590/CA/NCI NIH HHS; R01 CA078590-12/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Drugs, Investigational
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combinatorial Domain Hunting: solving problems in protein expression.
Next Document:  Radiation-induced premature senescence is associated with specific cytogenetic changes.